Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density

Autor: Robert Eriksson, Brian V. Broberg, Pelle L. Ishøy, Nikolaj Bak, Ulrik B. Andersen, Niklas R. Jørgensen, Filip K. Knop, Bjørn H. Ebdrup

Publikováno v: Frontiers in Psychiatry, Vol 9 (2019)

Background: Low bone mineral density (BMD) may constitute an underestimated comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may also a

Externí odkaz: https://doaj.org/article/96668b960e5b4b0eb02e97e74946f9ca

Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis

Autor: Kate Merritt, Andrew J. Lawrence, Arsime Demjaha, Kie W Nam, Roberto Rodriguez-Jimenez, Gareth J. Barker, Marina Díaz-Marsá, Brian V. Broberg, Richard Drake, Antje A. T. S. Reinders, Iris E. C. Sommer, Silvana Galderisi, Covadonga M. Díaz-Caneja, Birte Glenthøj, Kyra-Verena Sendt, Alice Egerton, Egill Rostrup, Armida Mucci, Inge Winter van Rossum, Neeltje E.M. van Haren, W. Wolfgang Fleischhacker, Lone Baandrup, Paola Dazzan, Shôn Lewis, René S. Kahn, Celso Arango, Bjørn H Ebdrup, Rocío Pérez-Iglesias, Mark Weiser, Philip McGuire, Christos Pantelis, Joost Janssen

Publikováno v: Schizophrenia Bulletin, 47(2), 444-455. Oxford University Press
Schizophr Bull
Dazzan, P, Lawrence, A J, Reinders, A A T S, Egerton, A, Van Haren, N E M, Merritt, K, Barker, G J, Perez-Iglesias, R, Sendt, K-V, Demjaha, A, Nam, K W, Sommer, I E, Pantelis, C, Wolfgang Fleischhacker, W, Van Rossum, I W, Galderisi, S, Mucci, A, Drake, R, Lewis, S, Weiser, M, Martinez Diaz-Caneja, C M, Janssen, J, Diaz-Marsa, M, Rodríguez-Jimenez, R, Arango, C, Baandrup, L, Broberg, B, Rostrup, E, Ebdrup, B H, Glenthøj, B, Kahn, R S & McGuire, P 2021, ' Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study ', Schizophrenia Bulletin, vol. 47, no. 2, pp. 444-455 . https://doi.org/10.1093/schbul/sbaa115

Individuals with psychoses have brain alterations, particularly in frontal and temporal cortices, that may be particularly prominent, already at illness onset, in those more likely to have poorer symptom remission following treatment with the first a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a012f668bb77a4815793528fa4d690e8
https://hdl.handle.net/11370/b622b771-5a00-4ac7-a90b-3a3596351ede

Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Naïve Patients With First-Episode Psychosis

Autor: Anders N Myken, Bjørn H Ebdrup, Mikkel E Sørensen, Brian V Broberg, Martin W Skjerbæk, Birte Y Glenthøj, Jens Lykkesfeldt, Mette Ø Nielsen

Publikováno v: Myken, A N, Ebdrup, B H, Sørensen, M E, Broberg, B V, Skjerbæk, M W, Glenthøj, B Y, Lykkesfeldt, J & Nielsen, M 2022, ' Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Naïve Patients With First-Episode Psychosis ', The international journal of neuropsychopharmacology, vol. 25, no. 8, pp. 613-618 . https://doi.org/10.1093/ijnp/pyac029

Low levels of vitamin C have been observed in patients with schizophrenia and psychosis, and vitamin C may affect the dopaminergic system. Likewise, antipsychotic medication modulates striatal dopamine D2 receptors. We measured vitamin C levels in 52

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30207d912bfe73e6fa26dd1d2ddfcba9
https://curis.ku.dk/portal/da/publications/lower-vitamin-c-levels-are-associated-with-less-improvement-in-negative-symptoms-in-initially-antipsychoticnaive-patients-with-firstepisode-psychosis(be76dbd1-617e-47d7-bfc0-f721d90b7ac5).html

Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis

Autor: Kasper Jessen, Henrik Larsson, Gitte Saltoft Andersen, Birte Glenthøj, Brian V. Broberg, Karen Tangmose, Egill Rostrup, Birgitte Fagerlund, Richard A.E. Edden, Anne Sigvard, Kirsten Borup Bojesen, Marie Bjerregaard Thomas, Mette Ødegaard Nielsen

Publikováno v: Bojesen, K B, Broberg, B V, Fagerlund, B, Jessen, K, Thomas, M B, Sigvard, A, Tangmose, K, Nielsen, M Ø, Andersen, G S, Larsson, H B W, Edden, R A E, Rostrup, E & Glenthøj, B Y 2021, ' Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis ', Biological Psychiatry, vol. 89, no. 3, pp. 78-87 . https://doi.org/10.1016/j.biopsych.2020.06.027
Biol Psychiatry

Background Abnormal glutamate and GABA (gamma-aminobutyric acid) levels have been found in the early phase of schizophrenia and may underlie cognitive deficits. However, the association between cognitive function and levels of glutamatergic metabolit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05a88c4760f4961255e73b527389609c
https://curis.ku.dk/ws/files/256890576/PIIS0006322320317376.pdf

Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis:Implications for clinical outcome after 12 months

Autor: Tina Dam Kristensen, Carsten Hjorthøj, Merete Nordentoft, Egill Rostrup, Kristine Krakauer, Brian V. Broberg, Birte Glenthøj, Louise Birkedal Glenthøj, Kirsten Borup Bojesen, Richard A.E. Edden, Christina Wenneberg, Birgitte Fagerlund

Publikováno v: Wenneberg, C, Glenthøj, B Y, Glenthøj, L B, Fagerlund, B, Krakauer, K, Kristensen, T D, Hjorthøj, C, Edden, R A E, Broberg, B V, Bojesen, K B, Rostrup, E & Nordentoft, M 2020, ' Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis : Implications for clinical outcome after 12 months ', European psychiatry : the journal of the Association of European Psychiatrists, vol. 63, no. 1, e83 . https://doi.org/10.1192/j.eurpsy.2020.77
European Psychiatry

Background. Cerebral glutamate and gamma-aminobutyric acid (GABA) levels might predict clinical outcome in individuals at ultrahigh risk (UHR) for psychosis but have previously primarily been investigated in smaller cohorts. We aimed to study whether

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7eb459068371faf658bef5e1627e093
https://curis.ku.dk/ws/files/249857946/Baseline_measures_of_cerebral_glutamate_and_GABA_levels_in_individuals_at_ultrahigh_risk_for_psychosis.pdf